Moderna (MRNA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA's Court Victory A German court ruled that BioNTech (BNTX ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases by the CEO and director. This comes as a significant ...

Scientists say that officials from the National Institutes of Health urged them to remove references to mRNA vaccine ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.